Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3705 in Isolated Methylmalonic Acidemia Due to MUT Deficiency
2022-502492-32-00Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Feb 2023
- Modality
- Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of mRNA-3705 in methylmalonic acidemia (MMA) (4 arms), sponsored by Moderna Inc. Primary endpoints: Part I: Incidence and severity of TEAEs, Part II: Percentage change in plasma methylmalonic acid at 3 months and 1 more. Started Feb 2023; status: completed.
02
Drugs
mRNA-3705
03
Conditions
methylmalonic acidemia (MMA)
Beyond the preview
Go deeper on 2022-502492-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502492-32-00.